Akebia Therapeutics (AKBA) Equity Average: 2016-2025
Historic Equity Average for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $35.4 million.
- Akebia Therapeutics' Equity Average rose 184.15% to $35.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.4 million, marking a year-over-year increase of 184.15%. This contributed to the annual value of -$39.9 million for FY2024, which is 214.62% down from last year.
- Latest data reveals that Akebia Therapeutics reported Equity Average of $35.4 million as of Q3 2025, which was up 31.62% from $26.9 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Equity Average registered a high of $229.1 million during Q1 2021, and its lowest value of -$772.9 million during Q4 2022.
- Moreover, its 3-year median value for Equity Average was -$28.9 million (2024), whereas its average is -$18.1 million.
- Per our database at Business Quant, Akebia Therapeutics' Equity Average plummeted by 832.02% in 2022 and then soared by 188.19% in 2025.
- Akebia Therapeutics' Equity Average (Quarterly) stood at $105.6 million in 2021, then tumbled by 832.02% to -$772.9 million in 2022, then soared by 95.47% to -$35.0 million in 2023, then slumped by 42.25% to -$49.8 million in 2024, then spiked by 184.15% to $35.4 million in 2025.
- Its Equity Average was $35.4 million in Q3 2025, compared to $26.9 million in Q2 2025 and -$12.3 million in Q1 2025.